George Golumbes­ki signs on at a Eu­ro­pean spe­cial­ist VC firm with $265M to bet on ge­net­ic dis­eases

Since de­camp­ing from Cel­gene dur­ing a man­age­ment over­haul close to three years ago, George Golumbes­ki has been chan­nel­ing years of con­nec­tions and deal­mak­ing ex­pe­ri­ence …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER